Human eye anatomy, retina, optic disc artery and vein etc.
Credit: lightmemorystock/Getty Images

A large real-world study has linked statin use to a lower risk of developing open-angle glaucoma and a reduced need for surgery, laser treatment, or additional eye drops among people who already have the disease.

Glaucoma, the leading cause of irreversible blindness worldwide, results from permanent damage to the optic nerve. Lowering eye pressure is the only modifiable risk factor proven to matter, yet many patients continue to worsen despite treatment.

Statins, widely prescribed to lower cholesterol, have drawn interest for potential neuroprotective effects, but their role in glaucoma is poorly understood. In this study, published in the British Journal of Ophthalmology, researchers used TriNetX, a global database of de-identified health records covering about 165 million people. The incidence analysis included 210,701 matched patients over 40 with ophthalmologic follow-up. At five years, statin use was associated with a 15% lower risk of developing open-angle glaucoma (HR 0.85); 2.3% of statin users were diagnosed versus 2.6% of controls. At 10 years the reduction was 10%.

A separate analysis of 29,598 matched patients with existing glaucoma examined “treatment escalation.” At five years, statin use was associated with a 36% lower risk of incisional glaucoma surgery, a 55% lower risk of minimally invasive glaucoma surgery (MIGS), and a 60% lower risk of selective laser trabeculoplasty (SLT), a procedure that uses laser pulses to improve fluid drainage. Statin users were also 11% less likely to be prescribed pressure-lowering eye drops.

At 10 years the associations persisted but were generally smaller, with 32%, 46%, and 51% reductions for the three procedures and 12% for eye drops. The authors note this is somewhat consistent with studies suggesting longer use may carry higher risk. Results were consistent for atorvastatin and rosuvastatin users but varied for other statins, possibly because those groups were much smaller.

The authors point to several possible mechanisms, including effects on immune cell activity, improved retinal blood flow, and reduced oxidative damage.

The study is observational and cannot establish cause and effect. The database lacked eye pressure readings, visual field tests, and optic nerve imaging, so the researchers could not measure progression directly and used treatment escalation as a rough stand-in. They could not tell why procedures were performed, which could reflect worsening disease but also poor medication adherence or intolerance. Propensity matching accounts only for variables in health records, so unmeasured factors such as adherence and statin dose may have influenced results, and the team could not account for eye drop use during the study.

The authors say the findings add to evidence on neuroprotective agents in glaucoma. “Prospective randomized trials are needed to better understand the effects of statin use on glaucoma incidence and treatment,” they concluded.

Also of Interest